Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-HCC01: rilvegostomig plus bevacizumab with or without tremelimumab versus atezolizumab plus bevacizumab in first-line advanced hepatocellular carcinoma
jRCT2051250018Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of rilvegostomig, bevacizumab, tremelimumab and atezolizumab in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Started May 2025; status: recruiting.
02
Drugs
rilvegostomigbevacizumabtremelimumabatezolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2051250018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250018.